nodes	percent_of_prediction	percent_of_DWPC	metapath
Carvedilol—VEGFA—head and neck cancer	0.436	0.675	CbGaD
Carvedilol—CYP1A1—head and neck cancer	0.211	0.326	CbGaD
Carvedilol—CYP2D6—Hydroxyurea—head and neck cancer	0.0266	0.3	CbGbCtD
Carvedilol—CYP1A2—Fluorouracil—head and neck cancer	0.0124	0.139	CbGbCtD
Carvedilol—CYP2C9—Fluorouracil—head and neck cancer	0.0111	0.125	CbGbCtD
Carvedilol—ABCB1—Vinblastine—head and neck cancer	0.01	0.113	CbGbCtD
Carvedilol—CYP2D6—Vinblastine—head and neck cancer	0.00943	0.106	CbGbCtD
Carvedilol—ABCB1—Docetaxel—head and neck cancer	0.00825	0.0929	CbGbCtD
Carvedilol—CYP3A4—Vinblastine—head and neck cancer	0.006	0.0676	CbGbCtD
Carvedilol—CYP3A4—Docetaxel—head and neck cancer	0.00494	0.0557	CbGbCtD
Carvedilol—Poisoning—Hydroxyurea—head and neck cancer	0.00304	0.0383	CcSEcCtD
Carvedilol—Intoxication—Hydroxyurea—head and neck cancer	0.00304	0.0383	CcSEcCtD
Carvedilol—VCAM1—tongue—head and neck cancer	0.00298	0.0381	CbGeAlD
Carvedilol—GJA1—Vinorelbine—Vinblastine—head and neck cancer	0.00287	1	CbGdCrCtD
Carvedilol—HIF1A—hair follicle—head and neck cancer	0.00246	0.0314	CbGeAlD
Carvedilol—GJA1—hair follicle—head and neck cancer	0.00238	0.0304	CbGeAlD
Carvedilol—Prothrombin level decreased—Docetaxel—head and neck cancer	0.00222	0.028	CcSEcCtD
Carvedilol—NDUFC2—exocrine gland—head and neck cancer	0.00218	0.0278	CbGeAlD
Carvedilol—VCAM1—mouth—head and neck cancer	0.002	0.0256	CbGeAlD
Carvedilol—HIF1A—mouth—head and neck cancer	0.00193	0.0246	CbGeAlD
Carvedilol—GJA1—mouth—head and neck cancer	0.00187	0.0239	CbGeAlD
Carvedilol—VCAM1—neck—head and neck cancer	0.00171	0.0219	CbGeAlD
Carvedilol—Angina unstable—Docetaxel—head and neck cancer	0.00168	0.0212	CcSEcCtD
Carvedilol—HIF1A—neck—head and neck cancer	0.00165	0.0211	CbGeAlD
Carvedilol—NDUFC2—mouth—head and neck cancer	0.00163	0.0208	CbGeAlD
Carvedilol—GJA1—neck—head and neck cancer	0.0016	0.0204	CbGeAlD
Carvedilol—SELE—saliva-secreting gland—head and neck cancer	0.00145	0.0186	CbGeAlD
Carvedilol—NPPB—lymphoid tissue—head and neck cancer	0.00145	0.0185	CbGeAlD
Carvedilol—VCAM1—parotid gland—head and neck cancer	0.0014	0.0178	CbGeAlD
Carvedilol—NDUFC2—neck—head and neck cancer	0.00139	0.0178	CbGeAlD
Carvedilol—HIF1A—parotid gland—head and neck cancer	0.00134	0.0171	CbGeAlD
Carvedilol—VCAM1—saliva-secreting gland—head and neck cancer	0.00134	0.0171	CbGeAlD
Carvedilol—SELE—connective tissue—head and neck cancer	0.00134	0.0171	CbGeAlD
Carvedilol—Cerebrovascular disorder—Fluorouracil—head and neck cancer	0.00132	0.0166	CcSEcCtD
Carvedilol—GJA1—parotid gland—head and neck cancer	0.0013	0.0166	CbGeAlD
Carvedilol—HIF1A—saliva-secreting gland—head and neck cancer	0.00129	0.0164	CbGeAlD
Carvedilol—SELE—epithelium—head and neck cancer	0.00127	0.0162	CbGeAlD
Carvedilol—GJA1—saliva-secreting gland—head and neck cancer	0.00125	0.0159	CbGeAlD
Carvedilol—VCAM1—connective tissue—head and neck cancer	0.00123	0.0157	CbGeAlD
Carvedilol—HIF1A—connective tissue—head and neck cancer	0.00118	0.0151	CbGeAlD
Carvedilol—VCAM1—epithelium—head and neck cancer	0.00117	0.0149	CbGeAlD
Carvedilol—NPPB—head—head and neck cancer	0.00116	0.0149	CbGeAlD
Carvedilol—Sudden death—Fluorouracil—head and neck cancer	0.00115	0.0145	CcSEcCtD
Carvedilol—GJA1—connective tissue—head and neck cancer	0.00115	0.0146	CbGeAlD
Carvedilol—HIF1A—epithelium—head and neck cancer	0.00112	0.0143	CbGeAlD
Carvedilol—SELE—trachea—head and neck cancer	0.00112	0.0143	CbGeAlD
Carvedilol—GJA1—epithelium—head and neck cancer	0.00109	0.0139	CbGeAlD
Carvedilol—NDUFC2—saliva-secreting gland—head and neck cancer	0.00109	0.0139	CbGeAlD
Carvedilol—ADRB3—connective tissue—head and neck cancer	0.00105	0.0134	CbGeAlD
Carvedilol—VCAM1—trachea—head and neck cancer	0.00103	0.0132	CbGeAlD
Carvedilol—HIF1A—trachea—head and neck cancer	0.000992	0.0127	CbGeAlD
Carvedilol—SELE—lymphoid tissue—head and neck cancer	0.000976	0.0125	CbGeAlD
Carvedilol—GJA1—trachea—head and neck cancer	0.000962	0.0123	CbGeAlD
Carvedilol—NDUFC2—epithelium—head and neck cancer	0.000947	0.0121	CbGeAlD
Carvedilol—VCAM1—lymphoid tissue—head and neck cancer	0.000898	0.0115	CbGeAlD
Carvedilol—SELE—thyroid gland—head and neck cancer	0.000887	0.0113	CbGeAlD
Carvedilol—Hyperuricaemia—Hydroxyurea—head and neck cancer	0.000882	0.0111	CcSEcCtD
Carvedilol—Interstitial pneumonia—Docetaxel—head and neck cancer	0.000879	0.0111	CcSEcCtD
Carvedilol—HIF1A—lymphoid tissue—head and neck cancer	0.000864	0.011	CbGeAlD
Carvedilol—Creatinine increased—Hydroxyurea—head and neck cancer	0.000859	0.0108	CcSEcCtD
Carvedilol—GJA1—lymphoid tissue—head and neck cancer	0.000838	0.0107	CbGeAlD
Carvedilol—NDUFC2—trachea—head and neck cancer	0.000838	0.0107	CbGeAlD
Carvedilol—Blood uric acid increased—Hydroxyurea—head and neck cancer	0.000833	0.0105	CcSEcCtD
Carvedilol—VCAM1—thyroid gland—head and neck cancer	0.000816	0.0104	CbGeAlD
Carvedilol—SELE—head—head and neck cancer	0.000787	0.01	CbGeAlD
Carvedilol—HIF1A—thyroid gland—head and neck cancer	0.000785	0.01	CbGeAlD
Carvedilol—Blood urea increased—Hydroxyurea—head and neck cancer	0.000772	0.00974	CcSEcCtD
Carvedilol—GJA1—thyroid gland—head and neck cancer	0.000761	0.00972	CbGeAlD
Carvedilol—VEGFA—trachea—head and neck cancer	0.00076	0.0097	CbGeAlD
Carvedilol—Rash maculo-papular—Hydroxyurea—head and neck cancer	0.000744	0.00938	CcSEcCtD
Carvedilol—Myocardial ischaemia—Fluorouracil—head and neck cancer	0.000733	0.00924	CcSEcCtD
Carvedilol—NDUFC2—lymphoid tissue—head and neck cancer	0.00073	0.00932	CbGeAlD
Carvedilol—Pulmonary oedema—Hydroxyurea—head and neck cancer	0.000728	0.00919	CcSEcCtD
Carvedilol—VCAM1—head—head and neck cancer	0.000724	0.00924	CbGeAlD
Carvedilol—HIF1A—head—head and neck cancer	0.000696	0.00889	CbGeAlD
Carvedilol—GJA1—head—head and neck cancer	0.000675	0.00863	CbGeAlD
Carvedilol—Cerebrovascular accident—Vinblastine—head and neck cancer	0.000665	0.00838	CcSEcCtD
Carvedilol—NDUFC2—thyroid gland—head and neck cancer	0.000663	0.00846	CbGeAlD
Carvedilol—Renal failure acute—Hydroxyurea—head and neck cancer	0.000643	0.00812	CcSEcCtD
Carvedilol—Neuralgia—Docetaxel—head and neck cancer	0.000612	0.00772	CcSEcCtD
Carvedilol—VEGFA—thyroid gland—head and neck cancer	0.000601	0.00768	CbGeAlD
Carvedilol—Interstitial lung disease—Docetaxel—head and neck cancer	0.0006	0.00758	CcSEcCtD
Carvedilol—NDUFC2—head—head and neck cancer	0.000588	0.00751	CbGeAlD
Carvedilol—ADRA1D—epithelium—head and neck cancer	0.000561	0.00717	CbGeAlD
Carvedilol—Blood creatinine increased—Hydroxyurea—head and neck cancer	0.000556	0.00702	CcSEcCtD
Carvedilol—Rash erythematous—Docetaxel—head and neck cancer	0.000555	0.007	CcSEcCtD
Carvedilol—SELE—lymph node—head and neck cancer	0.000551	0.00703	CbGeAlD
Carvedilol—Angina pectoris—Vinblastine—head and neck cancer	0.000548	0.00692	CcSEcCtD
Carvedilol—Rash maculo-papular—Fluorouracil—head and neck cancer	0.000535	0.00675	CcSEcCtD
Carvedilol—Pancytopenia—Vinblastine—head and neck cancer	0.000534	0.00674	CcSEcCtD
Carvedilol—Myocardial ischaemia—Docetaxel—head and neck cancer	0.000529	0.00667	CcSEcCtD
Carvedilol—VCAM1—lymph node—head and neck cancer	0.000507	0.00647	CbGeAlD
Carvedilol—Depression—Vinblastine—head and neck cancer	0.0005	0.00631	CcSEcCtD
Carvedilol—Acute coronary syndrome—Vinblastine—head and neck cancer	0.000495	0.00624	CcSEcCtD
Carvedilol—Myocardial infarction—Vinblastine—head and neck cancer	0.000492	0.00621	CcSEcCtD
Carvedilol—HIF1A—lymph node—head and neck cancer	0.000487	0.00623	CbGeAlD
Carvedilol—Pancytopenia—Hydroxyurea—head and neck cancer	0.000487	0.00615	CcSEcCtD
Carvedilol—Swelling—Fluorouracil—head and neck cancer	0.000485	0.00611	CcSEcCtD
Carvedilol—GJA1—lymph node—head and neck cancer	0.000473	0.00604	CbGeAlD
Carvedilol—Hyperbilirubinaemia—Docetaxel—head and neck cancer	0.000467	0.0059	CcSEcCtD
Carvedilol—Weight increased—Hydroxyurea—head and neck cancer	0.000467	0.00589	CcSEcCtD
Carvedilol—Amnesia—Fluorouracil—head and neck cancer	0.000455	0.00574	CcSEcCtD
Carvedilol—Haemoglobin—Vinblastine—head and neck cancer	0.000453	0.00571	CcSEcCtD
Carvedilol—CYP1A1—mouth—head and neck cancer	0.000452	0.00577	CbGeAlD
Carvedilol—Haemorrhage—Vinblastine—head and neck cancer	0.00045	0.00568	CcSEcCtD
Carvedilol—Hypoaesthesia—Vinblastine—head and neck cancer	0.000448	0.00566	CcSEcCtD
Carvedilol—Pharyngitis—Vinblastine—head and neck cancer	0.000447	0.00564	CcSEcCtD
Carvedilol—Hearing impaired—Docetaxel—head and neck cancer	0.000446	0.00563	CcSEcCtD
Carvedilol—Cardiac failure—Fluorouracil—head and neck cancer	0.000438	0.00553	CcSEcCtD
Carvedilol—ADRB1—connective tissue—head and neck cancer	0.00043	0.00549	CbGeAlD
Carvedilol—Gastrointestinal haemorrhage—Fluorouracil—head and neck cancer	0.000427	0.00539	CcSEcCtD
Carvedilol—Phosphatase alkaline increased—Docetaxel—head and neck cancer	0.000425	0.00536	CcSEcCtD
Carvedilol—Haemoglobin—Hydroxyurea—head and neck cancer	0.000413	0.00521	CcSEcCtD
Carvedilol—NDUFC2—lymph node—head and neck cancer	0.000412	0.00526	CbGeAlD
Carvedilol—Haemorrhage—Hydroxyurea—head and neck cancer	0.000411	0.00518	CcSEcCtD
Carvedilol—Cardiac arrest—Fluorouracil—head and neck cancer	0.000406	0.00513	CcSEcCtD
Carvedilol—Fluid retention—Docetaxel—head and neck cancer	0.000404	0.00509	CcSEcCtD
Carvedilol—Alopecia—Vinblastine—head and neck cancer	0.000398	0.00502	CcSEcCtD
Carvedilol—Nasopharyngitis—Fluorouracil—head and neck cancer	0.000382	0.00482	CcSEcCtD
Carvedilol—Lightheadedness—Docetaxel—head and neck cancer	0.00038	0.0048	CcSEcCtD
Carvedilol—Pulmonary oedema—Docetaxel—head and neck cancer	0.000378	0.00477	CcSEcCtD
Carvedilol—VEGFA—lymph node—head and neck cancer	0.000373	0.00477	CbGeAlD
Carvedilol—Angiopathy—Hydroxyurea—head and neck cancer	0.000373	0.0047	CcSEcCtD
Carvedilol—ADRA2C—parotid gland—head and neck cancer	0.000368	0.0047	CbGeAlD
Carvedilol—Ill-defined disorder—Vinblastine—head and neck cancer	0.000364	0.00459	CcSEcCtD
Carvedilol—Alopecia—Hydroxyurea—head and neck cancer	0.000363	0.00458	CcSEcCtD
Carvedilol—Anaemia—Vinblastine—head and neck cancer	0.000362	0.00457	CcSEcCtD
Carvedilol—Angina pectoris—Fluorouracil—head and neck cancer	0.00036	0.00454	CcSEcCtD
Carvedilol—ADRA1B—head—head and neck cancer	0.000356	0.00455	CbGeAlD
Carvedilol—Blood alkaline phosphatase increased—Docetaxel—head and neck cancer	0.000355	0.00448	CcSEcCtD
Carvedilol—Malaise—Vinblastine—head and neck cancer	0.000354	0.00446	CcSEcCtD
Carvedilol—Vertigo—Vinblastine—head and neck cancer	0.000352	0.00445	CcSEcCtD
Carvedilol—Leukopenia—Vinblastine—head and neck cancer	0.000351	0.00443	CcSEcCtD
Carvedilol—Pancytopenia—Fluorouracil—head and neck cancer	0.000351	0.00443	CcSEcCtD
Carvedilol—Swelling—Docetaxel—head and neck cancer	0.00035	0.00441	CcSEcCtD
Carvedilol—ADRA1D—head—head and neck cancer	0.000348	0.00445	CbGeAlD
Carvedilol—Upper respiratory tract infection—Fluorouracil—head and neck cancer	0.000343	0.00433	CcSEcCtD
Carvedilol—Convulsion—Vinblastine—head and neck cancer	0.00034	0.00429	CcSEcCtD
Carvedilol—Hypertension—Vinblastine—head and neck cancer	0.000339	0.00427	CcSEcCtD
Carvedilol—Photosensitivity reaction—Fluorouracil—head and neck cancer	0.000337	0.00425	CcSEcCtD
Carvedilol—Ill-defined disorder—Hydroxyurea—head and neck cancer	0.000332	0.00419	CcSEcCtD
Carvedilol—Pneumonia—Fluorouracil—head and neck cancer	0.000331	0.00418	CcSEcCtD
Carvedilol—Anaemia—Hydroxyurea—head and neck cancer	0.000331	0.00417	CcSEcCtD
Carvedilol—Discomfort—Vinblastine—head and neck cancer	0.00033	0.00416	CcSEcCtD
Carvedilol—Atrial fibrillation—Docetaxel—head and neck cancer	0.000326	0.00411	CcSEcCtD
Carvedilol—Acute coronary syndrome—Fluorouracil—head and neck cancer	0.000325	0.0041	CcSEcCtD
Carvedilol—Renal impairment—Docetaxel—head and neck cancer	0.000324	0.00409	CcSEcCtD
Carvedilol—Myocardial infarction—Fluorouracil—head and neck cancer	0.000323	0.00407	CcSEcCtD
Carvedilol—Malaise—Hydroxyurea—head and neck cancer	0.000323	0.00407	CcSEcCtD
Carvedilol—ADRA1A—epithelium—head and neck cancer	0.000322	0.00412	CbGeAlD
Carvedilol—Urinary tract infection—Fluorouracil—head and neck cancer	0.00032	0.00404	CcSEcCtD
Carvedilol—Leukopenia—Hydroxyurea—head and neck cancer	0.00032	0.00404	CcSEcCtD
Carvedilol—Cardiac failure—Docetaxel—head and neck cancer	0.000316	0.00399	CcSEcCtD
Carvedilol—CYP1A1—parotid gland—head and neck cancer	0.000315	0.00402	CbGeAlD
Carvedilol—Thrombocytopenia—Vinblastine—head and neck cancer	0.000313	0.00395	CcSEcCtD
Carvedilol—Convulsion—Hydroxyurea—head and neck cancer	0.00031	0.00391	CcSEcCtD
Carvedilol—Hyponatraemia—Docetaxel—head and neck cancer	0.00031	0.00391	CcSEcCtD
Carvedilol—Sinusitis—Fluorouracil—head and neck cancer	0.000309	0.0039	CcSEcCtD
Carvedilol—Gastrointestinal haemorrhage—Docetaxel—head and neck cancer	0.000309	0.00389	CcSEcCtD
Carvedilol—Pain in extremity—Docetaxel—head and neck cancer	0.000309	0.00389	CcSEcCtD
Carvedilol—Anorexia—Vinblastine—head and neck cancer	0.000305	0.00385	CcSEcCtD
Carvedilol—Migraine—Docetaxel—head and neck cancer	0.000304	0.00383	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.000302	0.00382	CcSEcCtD
Carvedilol—Discomfort—Hydroxyurea—head and neck cancer	0.000301	0.0038	CcSEcCtD
Carvedilol—Haemoglobin—Fluorouracil—head and neck cancer	0.000297	0.00375	CcSEcCtD
Carvedilol—Rhinitis—Fluorouracil—head and neck cancer	0.000296	0.00374	CcSEcCtD
Carvedilol—Haemorrhage—Fluorouracil—head and neck cancer	0.000296	0.00373	CcSEcCtD
Carvedilol—Hypoaesthesia—Fluorouracil—head and neck cancer	0.000294	0.00371	CcSEcCtD
Carvedilol—Pharyngitis—Fluorouracil—head and neck cancer	0.000293	0.0037	CcSEcCtD
Carvedilol—Oedema—Hydroxyurea—head and neck cancer	0.000292	0.00368	CcSEcCtD
Carvedilol—Infection—Hydroxyurea—head and neck cancer	0.00029	0.00366	CcSEcCtD
Carvedilol—Paraesthesia—Vinblastine—head and neck cancer	0.000287	0.00363	CcSEcCtD
Carvedilol—Dehydration—Docetaxel—head and neck cancer	0.000287	0.00362	CcSEcCtD
Carvedilol—Thrombocytopenia—Hydroxyurea—head and neck cancer	0.000286	0.00361	CcSEcCtD
Carvedilol—Skin disorder—Hydroxyurea—head and neck cancer	0.000284	0.00358	CcSEcCtD
Carvedilol—Orthostatic hypotension—Docetaxel—head and neck cancer	0.000282	0.00356	CcSEcCtD
Carvedilol—Anorexia—Hydroxyurea—head and neck cancer	0.000278	0.00351	CcSEcCtD
Carvedilol—Decreased appetite—Vinblastine—head and neck cancer	0.000278	0.00351	CcSEcCtD
Carvedilol—Cramp muscle—Docetaxel—head and neck cancer	0.000278	0.00351	CcSEcCtD
Carvedilol—Toxic epidermal necrolysis—Docetaxel—head and neck cancer	0.000278	0.00351	CcSEcCtD
Carvedilol—Aspartate aminotransferase increased—Docetaxel—head and neck cancer	0.000278	0.00351	CcSEcCtD
Carvedilol—Nasopharyngitis—Docetaxel—head and neck cancer	0.000276	0.00348	CcSEcCtD
Carvedilol—Pain—Vinblastine—head and neck cancer	0.000274	0.00345	CcSEcCtD
Carvedilol—Constipation—Vinblastine—head and neck cancer	0.000274	0.00345	CcSEcCtD
Carvedilol—Alanine aminotransferase increased—Docetaxel—head and neck cancer	0.000272	0.00343	CcSEcCtD
Carvedilol—ADRA2C—trachea—head and neck cancer	0.000272	0.00347	CbGeAlD
Carvedilol—Feeling abnormal—Vinblastine—head and neck cancer	0.000264	0.00333	CcSEcCtD
Carvedilol—CYP1A1—epithelium—head and neck cancer	0.000263	0.00336	CbGeAlD
Carvedilol—Bronchospasm—Docetaxel—head and neck cancer	0.000262	0.00331	CcSEcCtD
Carvedilol—Gastrointestinal pain—Vinblastine—head and neck cancer	0.000262	0.0033	CcSEcCtD
Carvedilol—Alopecia—Fluorouracil—head and neck cancer	0.000261	0.0033	CcSEcCtD
Carvedilol—Dyspnoea—Hydroxyurea—head and neck cancer	0.00026	0.00328	CcSEcCtD
Carvedilol—Angina pectoris—Docetaxel—head and neck cancer	0.00026	0.00328	CcSEcCtD
Carvedilol—Somnolence—Hydroxyurea—head and neck cancer	0.000259	0.00327	CcSEcCtD
Carvedilol—ADRA2A—connective tissue—head and neck cancer	0.000258	0.0033	CbGeAlD
Carvedilol—Dyspepsia—Hydroxyurea—head and neck cancer	0.000257	0.00324	CcSEcCtD
Carvedilol—Decreased appetite—Hydroxyurea—head and neck cancer	0.000254	0.0032	CcSEcCtD
Carvedilol—Pancytopenia—Docetaxel—head and neck cancer	0.000253	0.0032	CcSEcCtD
Carvedilol—ADRB1—head—head and neck cancer	0.000253	0.00323	CbGeAlD
Carvedilol—Abdominal pain—Vinblastine—head and neck cancer	0.000253	0.00319	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.000252	0.00318	CcSEcCtD
Carvedilol—Fatigue—Hydroxyurea—head and neck cancer	0.000252	0.00318	CcSEcCtD
Carvedilol—Constipation—Hydroxyurea—head and neck cancer	0.00025	0.00315	CcSEcCtD
Carvedilol—Pain—Hydroxyurea—head and neck cancer	0.00025	0.00315	CcSEcCtD
Carvedilol—ADRA1A—lymphoid tissue—head and neck cancer	0.000248	0.00317	CbGeAlD
Carvedilol—PTGS1—connective tissue—head and neck cancer	0.000243	0.00311	CbGeAlD
Carvedilol—Weight increased—Docetaxel—head and neck cancer	0.000243	0.00306	CcSEcCtD
Carvedilol—Vision blurred—Fluorouracil—head and neck cancer	0.000243	0.00306	CcSEcCtD
Carvedilol—Weight decreased—Docetaxel—head and neck cancer	0.000241	0.00304	CcSEcCtD
Carvedilol—Feeling abnormal—Hydroxyurea—head and neck cancer	0.000241	0.00303	CcSEcCtD
Carvedilol—Pneumonia—Docetaxel—head and neck cancer	0.000239	0.00302	CcSEcCtD
Carvedilol—Anaemia—Fluorouracil—head and neck cancer	0.000238	0.003	CcSEcCtD
Carvedilol—Hypersensitivity—Vinblastine—head and neck cancer	0.000236	0.00298	CcSEcCtD
Carvedilol—Stevens-Johnson syndrome—Docetaxel—head and neck cancer	0.000236	0.00297	CcSEcCtD
Carvedilol—Acute coronary syndrome—Docetaxel—head and neck cancer	0.000234	0.00296	CcSEcCtD
Carvedilol—Renal failure—Docetaxel—head and neck cancer	0.000234	0.00295	CcSEcCtD
Carvedilol—Myocardial infarction—Docetaxel—head and neck cancer	0.000233	0.00294	CcSEcCtD
Carvedilol—CYP1A1—trachea—head and neck cancer	0.000233	0.00297	CbGeAlD
Carvedilol—PTGS1—epithelium—head and neck cancer	0.000231	0.00295	CbGeAlD
Carvedilol—Body temperature increased—Hydroxyurea—head and neck cancer	0.000231	0.00291	CcSEcCtD
Carvedilol—Leukopenia—Fluorouracil—head and neck cancer	0.00023	0.00291	CcSEcCtD
Carvedilol—Asthenia—Vinblastine—head and neck cancer	0.00023	0.0029	CcSEcCtD
Carvedilol—Convulsion—Fluorouracil—head and neck cancer	0.000223	0.00281	CcSEcCtD
Carvedilol—Chest pain—Fluorouracil—head and neck cancer	0.000219	0.00277	CcSEcCtD
Carvedilol—Myalgia—Fluorouracil—head and neck cancer	0.000219	0.00277	CcSEcCtD
Carvedilol—Diarrhoea—Vinblastine—head and neck cancer	0.000219	0.00276	CcSEcCtD
Carvedilol—ADRA2A—trachea—head and neck cancer	0.000217	0.00277	CbGeAlD
Carvedilol—Discomfort—Fluorouracil—head and neck cancer	0.000217	0.00273	CcSEcCtD
Carvedilol—Hypersensitivity—Hydroxyurea—head and neck cancer	0.000215	0.00271	CcSEcCtD
Carvedilol—Haemoglobin—Docetaxel—head and neck cancer	0.000215	0.00271	CcSEcCtD
Carvedilol—Rhinitis—Docetaxel—head and neck cancer	0.000214	0.0027	CcSEcCtD
Carvedilol—Haemorrhage—Docetaxel—head and neck cancer	0.000213	0.00269	CcSEcCtD
Carvedilol—Hypoaesthesia—Docetaxel—head and neck cancer	0.000212	0.00268	CcSEcCtD
Carvedilol—Confusional state—Fluorouracil—head and neck cancer	0.000212	0.00267	CcSEcCtD
Carvedilol—Pharyngitis—Docetaxel—head and neck cancer	0.000212	0.00267	CcSEcCtD
Carvedilol—Dizziness—Vinblastine—head and neck cancer	0.000212	0.00267	CcSEcCtD
Carvedilol—Urinary tract disorder—Docetaxel—head and neck cancer	0.000211	0.00266	CcSEcCtD
Carvedilol—Oedema peripheral—Docetaxel—head and neck cancer	0.00021	0.00265	CcSEcCtD
Carvedilol—Oedema—Fluorouracil—head and neck cancer	0.00021	0.00265	CcSEcCtD
Carvedilol—Anaphylactic shock—Fluorouracil—head and neck cancer	0.00021	0.00265	CcSEcCtD
Carvedilol—Asthenia—Hydroxyurea—head and neck cancer	0.000209	0.00264	CcSEcCtD
Carvedilol—Urethral disorder—Docetaxel—head and neck cancer	0.000209	0.00264	CcSEcCtD
Carvedilol—Infection—Fluorouracil—head and neck cancer	0.000209	0.00263	CcSEcCtD
Carvedilol—Thrombocytopenia—Fluorouracil—head and neck cancer	0.000206	0.0026	CcSEcCtD
Carvedilol—Visual impairment—Docetaxel—head and neck cancer	0.000206	0.0026	CcSEcCtD
Carvedilol—Tachycardia—Fluorouracil—head and neck cancer	0.000205	0.00259	CcSEcCtD
Carvedilol—PTGS1—trachea—head and neck cancer	0.000204	0.00261	CbGeAlD
Carvedilol—Vomiting—Vinblastine—head and neck cancer	0.000203	0.00257	CcSEcCtD
Carvedilol—Erythema multiforme—Docetaxel—head and neck cancer	0.000202	0.00255	CcSEcCtD
Carvedilol—Headache—Vinblastine—head and neck cancer	0.000201	0.00253	CcSEcCtD
Carvedilol—Anorexia—Fluorouracil—head and neck cancer	0.0002	0.00253	CcSEcCtD
Carvedilol—ADRA1A—head—head and neck cancer	0.0002	0.00256	CbGeAlD
Carvedilol—Diarrhoea—Hydroxyurea—head and neck cancer	0.0002	0.00252	CcSEcCtD
Carvedilol—Hypotension—Fluorouracil—head and neck cancer	0.000196	0.00248	CcSEcCtD
Carvedilol—Angiopathy—Docetaxel—head and neck cancer	0.000194	0.00244	CcSEcCtD
Carvedilol—KCNH2—head—head and neck cancer	0.000193	0.00247	CbGeAlD
Carvedilol—Dizziness—Hydroxyurea—head and neck cancer	0.000193	0.00244	CcSEcCtD
Carvedilol—Immune system disorder—Docetaxel—head and neck cancer	0.000193	0.00243	CcSEcCtD
Carvedilol—Mediastinal disorder—Docetaxel—head and neck cancer	0.000192	0.00243	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Fluorouracil—head and neck cancer	0.000191	0.00242	CcSEcCtD
Carvedilol—ADRA2C—head—head and neck cancer	0.000191	0.00244	CbGeAlD
Carvedilol—Nausea—Vinblastine—head and neck cancer	0.00019	0.0024	CcSEcCtD
Carvedilol—Insomnia—Fluorouracil—head and neck cancer	0.00019	0.0024	CcSEcCtD
Carvedilol—Paraesthesia—Fluorouracil—head and neck cancer	0.000189	0.00238	CcSEcCtD
Carvedilol—Alopecia—Docetaxel—head and neck cancer	0.000189	0.00238	CcSEcCtD
Carvedilol—Dyspnoea—Fluorouracil—head and neck cancer	0.000187	0.00236	CcSEcCtD
Carvedilol—Somnolence—Fluorouracil—head and neck cancer	0.000187	0.00236	CcSEcCtD
Carvedilol—CYP1A2—thyroid gland—head and neck cancer	0.000187	0.00238	CbGeAlD
Carvedilol—Malnutrition—Docetaxel—head and neck cancer	0.000186	0.00234	CcSEcCtD
Carvedilol—Vomiting—Hydroxyurea—head and neck cancer	0.000186	0.00234	CcSEcCtD
Carvedilol—Dyspepsia—Fluorouracil—head and neck cancer	0.000185	0.00233	CcSEcCtD
Carvedilol—CYP2E1—lymphoid tissue—head and neck cancer	0.000185	0.00236	CbGeAlD
Carvedilol—Rash—Hydroxyurea—head and neck cancer	0.000184	0.00232	CcSEcCtD
Carvedilol—CYP1A1—thyroid gland—head and neck cancer	0.000184	0.00235	CbGeAlD
Carvedilol—Dermatitis—Hydroxyurea—head and neck cancer	0.000184	0.00232	CcSEcCtD
Carvedilol—Headache—Hydroxyurea—head and neck cancer	0.000183	0.00231	CcSEcCtD
Carvedilol—Decreased appetite—Fluorouracil—head and neck cancer	0.000183	0.0023	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.000181	0.00229	CcSEcCtD
Carvedilol—Back pain—Docetaxel—head and neck cancer	0.00018	0.00227	CcSEcCtD
Carvedilol—Pain—Fluorouracil—head and neck cancer	0.00018	0.00227	CcSEcCtD
Carvedilol—Muscle spasms—Docetaxel—head and neck cancer	0.000179	0.00225	CcSEcCtD
Carvedilol—Nausea—Hydroxyurea—head and neck cancer	0.000173	0.00219	CcSEcCtD
Carvedilol—Feeling abnormal—Fluorouracil—head and neck cancer	0.000173	0.00218	CcSEcCtD
Carvedilol—Anaemia—Docetaxel—head and neck cancer	0.000172	0.00217	CcSEcCtD
Carvedilol—ADRA2A—thyroid gland—head and neck cancer	0.000171	0.00219	CbGeAlD
Carvedilol—CYP2E1—thyroid gland—head and neck cancer	0.000168	0.00214	CbGeAlD
Carvedilol—Urticaria—Fluorouracil—head and neck cancer	0.000167	0.00211	CcSEcCtD
Carvedilol—Syncope—Docetaxel—head and neck cancer	0.000167	0.0021	CcSEcCtD
Carvedilol—Leukopenia—Docetaxel—head and neck cancer	0.000166	0.0021	CcSEcCtD
Carvedilol—Body temperature increased—Fluorouracil—head and neck cancer	0.000166	0.0021	CcSEcCtD
Carvedilol—Palpitations—Docetaxel—head and neck cancer	0.000164	0.00207	CcSEcCtD
Carvedilol—Loss of consciousness—Docetaxel—head and neck cancer	0.000163	0.00206	CcSEcCtD
Carvedilol—CYP1A1—head—head and neck cancer	0.000163	0.00208	CbGeAlD
Carvedilol—Cough—Docetaxel—head and neck cancer	0.000162	0.00205	CcSEcCtD
Carvedilol—PTGS1—thyroid gland—head and neck cancer	0.000162	0.00206	CbGeAlD
Carvedilol—Convulsion—Docetaxel—head and neck cancer	0.000161	0.00203	CcSEcCtD
Carvedilol—Hypertension—Docetaxel—head and neck cancer	0.00016	0.00202	CcSEcCtD
Carvedilol—Chest pain—Docetaxel—head and neck cancer	0.000158	0.002	CcSEcCtD
Carvedilol—Myalgia—Docetaxel—head and neck cancer	0.000158	0.002	CcSEcCtD
Carvedilol—Arthralgia—Docetaxel—head and neck cancer	0.000158	0.002	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.000157	0.00198	CcSEcCtD
Carvedilol—Hypersensitivity—Fluorouracil—head and neck cancer	0.000155	0.00195	CcSEcCtD
Carvedilol—Dry mouth—Docetaxel—head and neck cancer	0.000155	0.00195	CcSEcCtD
Carvedilol—Confusional state—Docetaxel—head and neck cancer	0.000153	0.00193	CcSEcCtD
Carvedilol—ADRA2A—head—head and neck cancer	0.000152	0.00194	CbGeAlD
Carvedilol—Anaphylactic shock—Docetaxel—head and neck cancer	0.000152	0.00191	CcSEcCtD
Carvedilol—Oedema—Docetaxel—head and neck cancer	0.000152	0.00191	CcSEcCtD
Carvedilol—Infection—Docetaxel—head and neck cancer	0.000151	0.0019	CcSEcCtD
Carvedilol—Shock—Docetaxel—head and neck cancer	0.000149	0.00188	CcSEcCtD
Carvedilol—CYP2E1—head—head and neck cancer	0.000149	0.0019	CbGeAlD
Carvedilol—Pruritus—Fluorouracil—head and neck cancer	0.000149	0.00188	CcSEcCtD
Carvedilol—Thrombocytopenia—Docetaxel—head and neck cancer	0.000148	0.00187	CcSEcCtD
Carvedilol—Tachycardia—Docetaxel—head and neck cancer	0.000148	0.00187	CcSEcCtD
Carvedilol—Skin disorder—Docetaxel—head and neck cancer	0.000147	0.00186	CcSEcCtD
Carvedilol—Anorexia—Docetaxel—head and neck cancer	0.000145	0.00182	CcSEcCtD
Carvedilol—Diarrhoea—Fluorouracil—head and neck cancer	0.000144	0.00181	CcSEcCtD
Carvedilol—PTGS1—head—head and neck cancer	0.000143	0.00183	CbGeAlD
Carvedilol—Hypotension—Docetaxel—head and neck cancer	0.000142	0.00179	CcSEcCtD
Carvedilol—Dizziness—Fluorouracil—head and neck cancer	0.000139	0.00175	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Docetaxel—head and neck cancer	0.000138	0.00174	CcSEcCtD
Carvedilol—Insomnia—Docetaxel—head and neck cancer	0.000137	0.00173	CcSEcCtD
Carvedilol—ABCB1—epithelium—head and neck cancer	0.000137	0.00174	CbGeAlD
Carvedilol—Paraesthesia—Docetaxel—head and neck cancer	0.000136	0.00172	CcSEcCtD
Carvedilol—KCNH2—lymph node—head and neck cancer	0.000135	0.00173	CbGeAlD
Carvedilol—Dyspnoea—Docetaxel—head and neck cancer	0.000135	0.00171	CcSEcCtD
Carvedilol—Somnolence—Docetaxel—head and neck cancer	0.000135	0.0017	CcSEcCtD
Carvedilol—Vomiting—Fluorouracil—head and neck cancer	0.000134	0.00169	CcSEcCtD
Carvedilol—ADRA2C—lymph node—head and neck cancer	0.000134	0.00171	CbGeAlD
Carvedilol—Dyspepsia—Docetaxel—head and neck cancer	0.000133	0.00168	CcSEcCtD
Carvedilol—Rash—Fluorouracil—head and neck cancer	0.000132	0.00167	CcSEcCtD
Carvedilol—Dermatitis—Fluorouracil—head and neck cancer	0.000132	0.00167	CcSEcCtD
Carvedilol—Decreased appetite—Docetaxel—head and neck cancer	0.000132	0.00166	CcSEcCtD
Carvedilol—Headache—Fluorouracil—head and neck cancer	0.000132	0.00166	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.000131	0.00165	CcSEcCtD
Carvedilol—Fatigue—Docetaxel—head and neck cancer	0.000131	0.00165	CcSEcCtD
Carvedilol—Pain—Docetaxel—head and neck cancer	0.00013	0.00164	CcSEcCtD
Carvedilol—Constipation—Docetaxel—head and neck cancer	0.00013	0.00164	CcSEcCtD
Carvedilol—Feeling abnormal—Docetaxel—head and neck cancer	0.000125	0.00158	CcSEcCtD
Carvedilol—Nausea—Fluorouracil—head and neck cancer	0.000125	0.00157	CcSEcCtD
Carvedilol—Gastrointestinal pain—Docetaxel—head and neck cancer	0.000124	0.00156	CcSEcCtD
Carvedilol—ABCB1—trachea—head and neck cancer	0.000121	0.00154	CbGeAlD
Carvedilol—Abdominal pain—Docetaxel—head and neck cancer	0.00012	0.00151	CcSEcCtD
Carvedilol—Body temperature increased—Docetaxel—head and neck cancer	0.00012	0.00151	CcSEcCtD
Carvedilol—CYP2D6—head—head and neck cancer	0.000118	0.00151	CbGeAlD
Carvedilol—CYP1A1—lymph node—head and neck cancer	0.000114	0.00146	CbGeAlD
Carvedilol—Hypersensitivity—Docetaxel—head and neck cancer	0.000112	0.00141	CcSEcCtD
Carvedilol—Asthenia—Docetaxel—head and neck cancer	0.000109	0.00137	CcSEcCtD
Carvedilol—Pruritus—Docetaxel—head and neck cancer	0.000107	0.00135	CcSEcCtD
Carvedilol—ADRA2A—lymph node—head and neck cancer	0.000107	0.00136	CbGeAlD
Carvedilol—ABCB1—lymphoid tissue—head and neck cancer	0.000105	0.00134	CbGeAlD
Carvedilol—Diarrhoea—Docetaxel—head and neck cancer	0.000104	0.00131	CcSEcCtD
Carvedilol—PTGS1—lymph node—head and neck cancer	0.0001	0.00128	CbGeAlD
Carvedilol—Dizziness—Docetaxel—head and neck cancer	0.0001	0.00127	CcSEcCtD
Carvedilol—Vomiting—Docetaxel—head and neck cancer	9.64e-05	0.00122	CcSEcCtD
Carvedilol—Rash—Docetaxel—head and neck cancer	9.56e-05	0.00121	CcSEcCtD
Carvedilol—ABCB1—thyroid gland—head and neck cancer	9.56e-05	0.00122	CbGeAlD
Carvedilol—Dermatitis—Docetaxel—head and neck cancer	9.55e-05	0.00121	CcSEcCtD
Carvedilol—Headache—Docetaxel—head and neck cancer	9.5e-05	0.0012	CcSEcCtD
Carvedilol—Nausea—Docetaxel—head and neck cancer	9.01e-05	0.00114	CcSEcCtD
Carvedilol—ABCB1—head—head and neck cancer	8.48e-05	0.00108	CbGeAlD
Carvedilol—ABCB1—lymph node—head and neck cancer	5.94e-05	0.000758	CbGeAlD
Carvedilol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	7.88e-06	7.55e-05	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—IL2—head and neck cancer	7.85e-06	7.52e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—IL2—head and neck cancer	7.67e-06	7.35e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—HRAS—head and neck cancer	7.63e-06	7.31e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—MAPK3—head and neck cancer	7.63e-06	7.3e-05	CbGpPWpGaD
Carvedilol—ADRA1D—GPCR downstream signaling—PIK3CA—head and neck cancer	7.61e-06	7.29e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—MAPK3—head and neck cancer	7.59e-06	7.27e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—MAPK3—head and neck cancer	7.57e-06	7.25e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—MAPK3—head and neck cancer	7.56e-06	7.24e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—NOTCH1—head and neck cancer	7.54e-06	7.22e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—MAPK3—head and neck cancer	7.46e-06	7.14e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—NOTCH1—head and neck cancer	7.42e-06	7.1e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—DPYD—head and neck cancer	7.29e-06	6.98e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—MAPK1—head and neck cancer	7.26e-06	6.95e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—EGFR—head and neck cancer	7.25e-06	6.95e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—MAPK1—head and neck cancer	7.22e-06	6.92e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—EGFR—head and neck cancer	7.22e-06	6.92e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—MAPK1—head and neck cancer	7.21e-06	6.9e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—EGFR—head and neck cancer	7.2e-06	6.9e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—MAPK1—head and neck cancer	7.19e-06	6.89e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—EGFR—head and neck cancer	7.19e-06	6.88e-05	CbGpPWpGaD
Carvedilol—XDH—Metabolism—AKT1—head and neck cancer	7.17e-06	6.87e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—IL2—head and neck cancer	7.13e-06	6.83e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—MAPK1—head and neck cancer	7.1e-06	6.8e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—EGFR—head and neck cancer	7.1e-06	6.8e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—MAPK3—head and neck cancer	7.06e-06	6.76e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—MAPK3—head and neck cancer	6.95e-06	6.65e-05	CbGpPWpGaD
Carvedilol—ADRB1—GPCR downstream signaling—PIK3CA—head and neck cancer	6.93e-06	6.64e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—YAP1—head and neck cancer	6.92e-06	6.63e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—PIK3CA—head and neck cancer	6.91e-06	6.62e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	6.88e-06	6.59e-05	CbGpPWpGaD
Carvedilol—ADRA2B—GPCR downstream signaling—PIK3CA—head and neck cancer	6.87e-06	6.58e-05	CbGpPWpGaD
Carvedilol—ADRB2—GPCR downstream signaling—PIK3CA—head and neck cancer	6.78e-06	6.5e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—TYMS—head and neck cancer	6.74e-06	6.46e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—AKT1—head and neck cancer	6.74e-06	6.45e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	6.74e-06	6.45e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—MAPK1—head and neck cancer	6.72e-06	6.43e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—EGFR—head and neck cancer	6.71e-06	6.43e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—PTGS2—head and neck cancer	6.69e-06	6.41e-05	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—PTGS2—head and neck cancer	6.68e-06	6.4e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—GSTM1—head and neck cancer	6.67e-06	6.39e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—MAPK1—head and neck cancer	6.61e-06	6.33e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—EGFR—head and neck cancer	6.61e-06	6.33e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—NOTCH1—head and neck cancer	6.59e-06	6.31e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	6.5e-06	6.23e-05	CbGpPWpGaD
Carvedilol—ADRA2C—GPCR downstream signaling—PIK3CA—head and neck cancer	6.42e-06	6.15e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—HRAS—head and neck cancer	6.39e-06	6.12e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—GPX1—head and neck cancer	6.38e-06	6.12e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—TYMS—head and neck cancer	6.36e-06	6.09e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—CYP1A1—head and neck cancer	6.32e-06	6.05e-05	CbGpPWpGaD
Carvedilol—ADRA1B—GPCR downstream signaling—PIK3CA—head and neck cancer	6.32e-06	6.05e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—TYMS—head and neck cancer	6.3e-06	6.04e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—PIK3CA—head and neck cancer	6.3e-06	6.03e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—GSTM1—head and neck cancer	6.28e-06	6.02e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—PIK3CA—head and neck cancer	6.27e-06	6e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—PIK3CA—head and neck cancer	6.25e-06	5.99e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—PIK3CA—head and neck cancer	6.24e-06	5.98e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—GSTM1—head and neck cancer	6.23e-06	5.97e-05	CbGpPWpGaD
Carvedilol—ADRA1D—GPCR downstream signaling—AKT1—head and neck cancer	6.22e-06	5.95e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—MAPK3—head and neck cancer	6.17e-06	5.91e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—PIK3CA—head and neck cancer	6.16e-06	5.9e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—IL2—head and neck cancer	6.15e-06	5.89e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—NOTCH1—head and neck cancer	6.12e-06	5.86e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—TP53—head and neck cancer	6.06e-06	5.81e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—TP53—head and neck cancer	6.05e-06	5.79e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—GPX1—head and neck cancer	6.02e-06	5.76e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—CCND1—head and neck cancer	5.99e-06	5.74e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—GPX1—head and neck cancer	5.96e-06	5.71e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—CYP1A1—head and neck cancer	5.96e-06	5.7e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—CYP1A1—head and neck cancer	5.9e-06	5.66e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	5.88e-06	5.63e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—MAPK1—head and neck cancer	5.87e-06	5.62e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—EGFR—head and neck cancer	5.87e-06	5.62e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—PTEN—head and neck cancer	5.84e-06	5.59e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—PIK3CA—head and neck cancer	5.83e-06	5.58e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—HRAS—head and neck cancer	5.83e-06	5.58e-05	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—PTEN—head and neck cancer	5.82e-06	5.58e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—HRAS—head and neck cancer	5.8e-06	5.55e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—PTEN—head and neck cancer	5.79e-06	5.54e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—HRAS—head and neck cancer	5.79e-06	5.54e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—HRAS—head and neck cancer	5.77e-06	5.53e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—PIK3CA—head and neck cancer	5.74e-06	5.49e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—MAPK3—head and neck cancer	5.73e-06	5.49e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—HRAS—head and neck cancer	5.7e-06	5.46e-05	CbGpPWpGaD
Carvedilol—ADRB1—GPCR downstream signaling—AKT1—head and neck cancer	5.66e-06	5.43e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—AKT1—head and neck cancer	5.65e-06	5.41e-05	CbGpPWpGaD
Carvedilol—ADRA2B—GPCR downstream signaling—AKT1—head and neck cancer	5.61e-06	5.38e-05	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR downstream signaling—PIK3CA—head and neck cancer	5.61e-06	5.37e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—IL2—head and neck cancer	5.6e-06	5.37e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—IL2—head and neck cancer	5.55e-06	5.32e-05	CbGpPWpGaD
Carvedilol—ADRB2—GPCR downstream signaling—AKT1—head and neck cancer	5.54e-06	5.31e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—IL2—head and neck cancer	5.48e-06	5.25e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—CCND1—head and neck cancer	5.46e-06	5.23e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—MAPK1—head and neck cancer	5.45e-06	5.22e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—EGFR—head and neck cancer	5.45e-06	5.22e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—PTGS2—head and neck cancer	5.44e-06	5.21e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—CCND1—head and neck cancer	5.41e-06	5.18e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—HRAS—head and neck cancer	5.39e-06	5.16e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—TYMS—head and neck cancer	5.38e-06	5.16e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—CCND1—head and neck cancer	5.34e-06	5.12e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—GSTM1—head and neck cancer	5.32e-06	5.1e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—HRAS—head and neck cancer	5.31e-06	5.08e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—PTEN—head and neck cancer	5.27e-06	5.05e-05	CbGpPWpGaD
Carvedilol—ADRA2C—GPCR downstream signaling—AKT1—head and neck cancer	5.24e-06	5.02e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—VEGFA—head and neck cancer	5.23e-06	5.01e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—PTEN—head and neck cancer	5.22e-06	5e-05	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—PIK3CA—head and neck cancer	5.21e-06	4.99e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—IL2—head and neck cancer	5.19e-06	4.97e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—STAT3—head and neck cancer	5.17e-06	4.96e-05	CbGpPWpGaD
Carvedilol—ADRA1B—GPCR downstream signaling—AKT1—head and neck cancer	5.16e-06	4.94e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—PTEN—head and neck cancer	5.16e-06	4.94e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—AKT1—head and neck cancer	5.14e-06	4.93e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—AKT1—head and neck cancer	5.12e-06	4.9e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—AKT1—head and neck cancer	5.11e-06	4.89e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—IL2—head and neck cancer	5.1e-06	4.89e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—GPX1—head and neck cancer	5.1e-06	4.88e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—AKT1—head and neck cancer	5.1e-06	4.88e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—PIK3CA—head and neck cancer	5.09e-06	4.88e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CCND1—head and neck cancer	5.06e-06	4.84e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—CYP1A1—head and neck cancer	5.05e-06	4.83e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—AKT1—head and neck cancer	5.03e-06	4.82e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—PTGS2—head and neck cancer	4.99e-06	4.78e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CCND1—head and neck cancer	4.98e-06	4.77e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—MAPK3—head and neck cancer	4.94e-06	4.74e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—PTEN—head and neck cancer	4.88e-06	4.67e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	4.85e-06	4.65e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—PTEN—head and neck cancer	4.8e-06	4.6e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—VEGFA—head and neck cancer	4.76e-06	4.56e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—AKT1—head and neck cancer	4.76e-06	4.56e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—PTEN—head and neck cancer	4.74e-06	4.54e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—PIK3CA—head and neck cancer	4.73e-06	4.53e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—VEGFA—head and neck cancer	4.72e-06	4.52e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—STAT3—head and neck cancer	4.72e-06	4.52e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—HRAS—head and neck cancer	4.71e-06	4.51e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—PTGS2—head and neck cancer	4.71e-06	4.51e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—MAPK1—head and neck cancer	4.7e-06	4.51e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—EGFR—head and neck cancer	4.7e-06	4.5e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—AKT1—head and neck cancer	4.69e-06	4.49e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—STAT3—head and neck cancer	4.67e-06	4.47e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—VEGFA—head and neck cancer	4.66e-06	4.46e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—STAT3—head and neck cancer	4.61e-06	4.42e-05	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR downstream signaling—AKT1—head and neck cancer	4.58e-06	4.39e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—IL2—head and neck cancer	4.53e-06	4.34e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—MAPK3—head and neck cancer	4.5e-06	4.31e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—MAPK3—head and neck cancer	4.46e-06	4.28e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CCND1—head and neck cancer	4.42e-06	4.23e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—VEGFA—head and neck cancer	4.41e-06	4.22e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—MAPK3—head and neck cancer	4.41e-06	4.22e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—HRAS—head and neck cancer	4.38e-06	4.19e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—STAT3—head and neck cancer	4.36e-06	4.18e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—PTEN—head and neck cancer	4.35e-06	4.17e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—VEGFA—head and neck cancer	4.34e-06	4.15e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—STAT3—head and neck cancer	4.3e-06	4.11e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—MAPK1—head and neck cancer	4.29e-06	4.11e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—EGFR—head and neck cancer	4.29e-06	4.1e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—PTEN—head and neck cancer	4.27e-06	4.09e-05	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—AKT1—head and neck cancer	4.26e-06	4.08e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—MAPK1—head and neck cancer	4.25e-06	4.07e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—EGFR—head and neck cancer	4.25e-06	4.07e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—IL2—head and neck cancer	4.21e-06	4.03e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—MAPK1—head and neck cancer	4.19e-06	4.02e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—EGFR—head and neck cancer	4.19e-06	4.02e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—MAPK3—head and neck cancer	4.17e-06	3.99e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—AKT1—head and neck cancer	4.16e-06	3.99e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—TYMS—head and neck cancer	4.16e-06	3.98e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	4.15e-06	3.97e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—PIK3CA—head and neck cancer	4.12e-06	3.94e-05	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—PIK3CA—head and neck cancer	4.11e-06	3.94e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—GSTM1—head and neck cancer	4.11e-06	3.93e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CCND1—head and neck cancer	4.11e-06	3.93e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—PTEN—head and neck cancer	4.1e-06	3.93e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—MAPK3—head and neck cancer	4.1e-06	3.93e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—PIK3CA—head and neck cancer	4.08e-06	3.91e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—MAPK1—head and neck cancer	3.97e-06	3.8e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—EGFR—head and neck cancer	3.97e-06	3.8e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—PTEN—head and neck cancer	3.96e-06	3.8e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—TP53—head and neck cancer	3.95e-06	3.78e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—GPX1—head and neck cancer	3.93e-06	3.77e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—MAPK1—head and neck cancer	3.9e-06	3.74e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—EGFR—head and neck cancer	3.9e-06	3.74e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—CYP1A1—head and neck cancer	3.89e-06	3.73e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—AKT1—head and neck cancer	3.87e-06	3.7e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—VEGFA—head and neck cancer	3.85e-06	3.69e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—STAT3—head and neck cancer	3.82e-06	3.65e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—HRAS—head and neck cancer	3.78e-06	3.62e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PTGS2—head and neck cancer	3.76e-06	3.6e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—PIK3CA—head and neck cancer	3.72e-06	3.56e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—PIK3CA—head and neck cancer	3.69e-06	3.53e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—MAPK3—head and neck cancer	3.64e-06	3.49e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—PIK3CA—head and neck cancer	3.64e-06	3.48e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—TP53—head and neck cancer	3.6e-06	3.45e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—VEGFA—head and neck cancer	3.58e-06	3.43e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—TP53—head and neck cancer	3.57e-06	3.41e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—STAT3—head and neck cancer	3.54e-06	3.4e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PTGS2—head and neck cancer	3.54e-06	3.39e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—TP53—head and neck cancer	3.52e-06	3.37e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PTGS2—head and neck cancer	3.51e-06	3.36e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—MAPK1—head and neck cancer	3.47e-06	3.32e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—EGFR—head and neck cancer	3.47e-06	3.32e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—PIK3CA—head and neck cancer	3.44e-06	3.3e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—HRAS—head and neck cancer	3.44e-06	3.3e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—HRAS—head and neck cancer	3.41e-06	3.27e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—PIK3CA—head and neck cancer	3.39e-06	3.25e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—MAPK3—head and neck cancer	3.39e-06	3.24e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—HRAS—head and neck cancer	3.37e-06	3.22e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—AKT1—head and neck cancer	3.36e-06	3.22e-05	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—AKT1—head and neck cancer	3.36e-06	3.22e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—PIK3CA—head and neck cancer	3.34e-06	3.2e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—AKT1—head and neck cancer	3.33e-06	3.19e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—TP53—head and neck cancer	3.33e-06	3.19e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PTEN—head and neck cancer	3.28e-06	3.14e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—TP53—head and neck cancer	3.28e-06	3.14e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—MAPK1—head and neck cancer	3.22e-06	3.09e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—EGFR—head and neck cancer	3.22e-06	3.09e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—HRAS—head and neck cancer	3.18e-06	3.05e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—HRAS—head and neck cancer	3.13e-06	3e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PTEN—head and neck cancer	3.09e-06	2.96e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—PIK3CA—head and neck cancer	3.07e-06	2.94e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PTEN—head and neck cancer	3.06e-06	2.93e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—AKT1—head and neck cancer	3.04e-06	2.91e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—AKT1—head and neck cancer	3.01e-06	2.88e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—PIK3CA—head and neck cancer	3.01e-06	2.88e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PTGS2—head and neck cancer	3e-06	2.87e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—AKT1—head and neck cancer	2.97e-06	2.85e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—TP53—head and neck cancer	2.91e-06	2.79e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—PIK3CA—head and neck cancer	2.9e-06	2.77e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—AKT1—head and neck cancer	2.81e-06	2.69e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—PIK3CA—head and neck cancer	2.8e-06	2.68e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—HRAS—head and neck cancer	2.78e-06	2.67e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—AKT1—head and neck cancer	2.77e-06	2.65e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—AKT1—head and neck cancer	2.73e-06	2.62e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—TP53—head and neck cancer	2.71e-06	2.59e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PTEN—head and neck cancer	2.62e-06	2.51e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—HRAS—head and neck cancer	2.59e-06	2.48e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—AKT1—head and neck cancer	2.51e-06	2.4e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—AKT1—head and neck cancer	2.46e-06	2.35e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—AKT1—head and neck cancer	2.37e-06	2.27e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PTGS2—head and neck cancer	2.32e-06	2.22e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PIK3CA—head and neck cancer	2.31e-06	2.21e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—AKT1—head and neck cancer	2.28e-06	2.19e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PIK3CA—head and neck cancer	2.18e-06	2.09e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PIK3CA—head and neck cancer	2.16e-06	2.07e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PTEN—head and neck cancer	2.02e-06	1.93e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—AKT1—head and neck cancer	1.89e-06	1.81e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PIK3CA—head and neck cancer	1.85e-06	1.77e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—AKT1—head and neck cancer	1.78e-06	1.71e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—AKT1—head and neck cancer	1.76e-06	1.69e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—AKT1—head and neck cancer	1.51e-06	1.44e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PIK3CA—head and neck cancer	1.42e-06	1.36e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—AKT1—head and neck cancer	1.16e-06	1.11e-05	CbGpPWpGaD
